HKB's NHP Passive Cutaneous Anaphylaxis (PCA) Models provide pharmaceutical researchers with robust platforms for investigating IgE-mediated type I hypersensitivity reactions. Our non-human primate models enable accurate assessment of anaphylaxis mechanisms and therapeutic intervention efficacy through well-established challenge protocols. The PCA assay serves as a critical preclinical tool for evaluating mast cell stabilizers, antihistamines, and biologic therapeutics targeting allergic inflammation.
HkeyBio is a China-based, globally-focused preclinical CRO dedicated exclusively to autoimmune and allergic diseases, with a unified service network across Asia, the Americas, Europe and Australia.
